PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Additional lines of treatment
PAD Profile : Additional lines of treatment
Keywords :
Biologic, NICE, JAK, Cytokine modulator, immunosuppressant, monoclonal antibody, biosimilar, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, csDMARD, conventional synthetic, targeted synthetic, tsDMARD, 4th line
RA (severe), RA (moderate), AS, NrSpA, PsA, Crohn's, UC, IBD, Psoriasis, Rheumatology, Dermatology, ankylosing spondylitis, non-radiographic spondyloarthritis, rheumatoid arthritis, ulcerative colitis, interleukin, IL-6, janus kinase inhibitor, sequential, additional, vedolizumab, adalimumab, infliximab, ustekinumab, etanercept, golimumab, guselkumab, tocolizumab, rituximab, ixekizumab, secukinumab, baracitinib, upadacitinib, certolizumab, filgotinib, sarilumab, apremilast, bimekizumab, brodalumab, dimethyl fumarate, risankizumab, tildrakizumab
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
No drugs returned.
Other Indications
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Osteoarthritis
- Erectile dysfunction
- Hyperuricaemia and Gout
- Dysphagia
- Low sexual desire in menopausal women
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Duchenne muscular dystrophy
- Multiple sclerosis
- Systemic Lupus Erythematosus
- Inclusion body myositis
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Systemic Lupus Erythematosus
- Multiple sclerosis
- Short bowel syndrome
- Any paediatric use
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Restless Leg Syndrome
- Pain (Chronic)
- Narcolepsy
- All
- Atopic dermatitis
- Psoriasis
- Inflammatory bowel disease
- Ulcerative colitis - moderately to severely active
- Migraine (prevention)
- Dry eyes
- Cancer
- Diarrhoea
- Ulcerative colitis - moderately to severely active
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
01 November 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed an updated version of the Standard Operating Process (SOP).
See additional documentation section.
05 July 2023
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Surrey Heartlands ICS Area Prescribing Committee (APC) has agreed an additional lines of treatment process and principles in conjunction with the local Rheumatology, Gastroenterology and Dermatology Clinical Networks.
Associated BNF Codes
01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
13. Skin
13.05.03. Drugs affecting the immune response